South Korean pharmaceutical company Celltrion Inc today announced positive results from its experimental treatment antibodies against COVID-19, which, as noted, is safe and reduces the treatment period by almost five days in Phase 3 of its global clinical trials.
The tests, which involved 1,315 people, have been conducted since January in 13 countries, including South Korea, the United States, Spain and Romania, Celltrion said in a statement.
This treatment slowed the severe symptoms of COVID-19 in more than 70% of patients, including the high-risk group with underlying diseases. It also reduced the recovery period by 4.9 days, according to the company, as broadcast by AMPE.
In February the South Korea It conditionally approved this antibody treatment, making it the first topical treatment for the disease caused by the new coronavirus that received such approval in the country. The company noted that it will seek its full approval based on the test results.
Shares of Celltrion rose as much as 5.6% in trading this morning, compared to a 0.3% drop in the broader market.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
